October 6, 2017 04:48 AM EDTUpdated 10:27 AM
R&D

In a set­back, Bay­er, J&J say their big PhI­II sec­ondary stroke tri­al for Xarel­to failed

John Carroll

Editor & Founder

Three years af­ter Bay­er and J&J be­gan re­cruit­ing more than 7,000 pa­tients for a big new Phase III study of Xarel­to as pre­ven­tive mea­sure against …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

TRENDING NOW

In sur­prise, study sug­gests Covid mR­NA vac­cines may boost can­cer im­munother­a­py ef­fi­ca­cy

Ex-Kite lead­ers step in at Kyver­na as CEO ex­its af­ter land­ing year's sec­ond-biggest IPO

Pfiz­er tees up Phase 3 test in weight man­age­ment — but in an un­ex­pect­ed area

BioN­Tech rolls out Phase 2 lung can­cer da­ta as VEGF bis­pecifics take cen­ter stage

Im­mat­ics los­es Bris­tol My­er­s' sup­port on Phase 1 bis­pe­cif­ic T cell en­gager

sponsored

Break­ing down si­los with a new quan­ti­ta­tive ap­proach to drug de­vel­op­ment

A service from the Financial Times